Abbott Laboratories Corporation

University of Georgia Research Foundation Inc

Massachusetts Institute of Technology

Michigan State University

Florida State University Research Foundation, Inc.

Kelley Wilson Moremen

James Michael Pierce

Richard D Cummings

John J Kopchick

Pedro A Prieto

David Fletcher Smith

Pradip Mukerji

Robert Samuel Langer

Joseph J Zimmermann

Ramnath Sasisekharan

J Michael Pierce

Jin Kyu Lee

Jenny Jie Yang

Charles L Cooney

Stephen Dalton

Ronald Carl Orlando

Robert Lance Wells

James A Atwood, Iii

Edward Brown

Michael Tiemeyer

William S York

Charles I Cooney

Jian Hu

Described herein are compounds that can bind CaSR and/or a CaSR extracellular domain and formulations thereof. Also described herein are methods of inhibiting CaSR and/or treating a disease or disorder associated with a mutation in CaSR by administering a compound or formulation thereof described herein. Also described herein are assays that can be used to identify compounds that can bind an extracellular domain of CaSR.

Calcium sensing receptors, ligands, compositions, and methods of use

The present invention relates to a method of isotopically labeling glycans and in facilitating high throughput quantitative/comparative analysis of glycomic compositions of biological cells. The method is applicable inter alia for identifying differentiated cells and their glycomic characteristics, differentiation conditions, disease and/or therapeutic progression, diagnosing disease states, determining drug activity, establishing manufacturing efficiencies and for determining the half-life of glycans in cells.

Vivo isotopic labeling method for quantitative glycomics

The present disclosure provides a novel family of C-type lectins from vertebrates. As specifically exemplified, this family of lectins includes a melibiose-specific lectin (XL35) from oocytes, and two human lectins, HL-3 and HL-13, specifically expressed in endothelial cells such as blood vessels, stomach, small intestine, heart and tissue and in small intestine, respectively. Amino acid sequences of the lectin proteins are provided herein, together with the nucleotide sequences encoding these proteins.

Lectins and coding sequences

The subject invention relates to methods of producing non-human transgenic mammals which produce various oligosaccharides and glycoconjugates in their milk. Additionally, the subject invention relates to the mammals themselves, the milk which they produce, compositions comprising the milk, fractions of the milk, and the purified oligosaccharides, as well as glyconjugates, present in the milk.

Transgenic non-human mammals expressing heterologous glycosyltransferase DNA sequences produce oligosaccharides and glycoproteins in their milk

The present disclosure provides a novel family of C-type lectins from vertebrates. As specifically exemplified, this family of lectins includes a melibiose-specific lectin (XL35) from Xenopus laevis oocytes, and two human lectins, HL-3 and HL-13, specifically expressed in endothelial cells such as blood vessels, stomach, small intestine, heart and tissue and in small intestine, respectively. Amino acid sequences of the lectin proteins are provided herein, together with the nucleotide sequences encoding these proteins.

The invention relates to humanized milk. The milk is produced by a non-human transgenic mammal wherein the genome of said transgenic non-human mammal contains at least one heterologous gene encoding for a human catalytic entity and wherein the catalytic entity produces oligosaccharides and glycoconjugates that are present in the milk of said transgenic non-human mammal. An especially useful catalytic entity is human glycosyltransferases which produce oligosaccharides and glyconjugates. Specifically exemplified, is the production of 2'-fucosyl-lactose in the milk of transgenic mice which contain and express a transgene encoding .alpha.-1,2-fucosyltransferase operatively linked to a mammary gland specific promoter. A method of obtaining humanized milk is disclosed. The method comprises the steps of (a) inserting into the genome of a non-human mammal a heterologous gene encoding the production of a human catalytic entity wherein said catalytic entity produces a secondary gene product in the milk of said non-human mammal; and (b) milking said non-human mammal. The humanized milk may be used in the preparation of an enteral nutritional product useful in the nutritive maintenance of an animal.

Oligosaccharides and glycoproteins produced in milk of transgenic

The invention relates to transgenic non-human mammals characterized in that the genome of said mammals contain at least one heterologous gene encoding for the production of heterologous catalytic entity selected from the group consisting of enzymes and antibodies, and wherein said catalytic entity produces a second heterologous product in the milk of said mammal. Especially useful in the practice of the invention are human glycosyltransferases and transgenic sheep, goats and cows. The heterologous product includes oligosaccharides and glycoconjugates. Specifically exemplified, is the production of 2'-fucosyl-lactose in the milk of transgenic mice which contain and express a transgene encoding .alpha.-1,2-fucosyltransferase operatively linked to a mammary gland specific promoter.

Transgenic non-human mammals producing oligosaccharides and

The cloning of the heparinase gene from Flavobacterium Heparinum using the polymerase chain reaction is described. The Open Reading Frame (ORF) corresponded to 1152 base pairs encoding a precursor protein of MW 43,800 daltons. The amino acid sequence reveals a 20-residue leader peptide. The gene was expressed in two expression systems in E. coli.

Method for obtaining a modified heparinase gene

The invention relates to the milk of a transgenic non-human mammal. The milk is characterized in that it contains heterologous components produced as the secondary gene products of a heterologous gene contained in the genome of the transgenic non-human mammal. The heterologous gene encodes a heterologous catalytic entity such as a human enzyme selected from the group consisting of glycosyltransferases, phosphorylases, hydroxylases, peptidases and sulfotransferases. Especially useful in the practice of the invention are human glycosyltransferases. The desired heterologous components include oligosaccahrides, glycoconjugates. Specifically exemplified, is the production of 2'-fucosyl-lactose in the milk of transgenic mice which contain and express a transgene encoding .alpha.-1,2-fucosyltransferase operatively linked to a mammary gland specific promoter. The oligosaccahrides and glycoconjugates may be isolated from the milk of the transgenic mammals and used in the preparation of pharmaceuticals, diagnostic kits, nutritional products and the like. The whole transgenic milk may also be used to formulate nutritional products that provide special advantages. The transgenic milk may also be used in the production of specialized enteral nutritional products.

Transgenic non-human mammal milk comprising 2'-fucosyl-lactose

Heparinase gene from flavobacterium heparinum

The invention relates to transgenic non-human mammals characterized in that the genome of said mammals contain at least one heterologous gene encoding for the production of heterologous catalytic entity selected from the group consisting of enzymes and antibodies, and wherein said catalytic entity produces a second heterologous product in the milk of said mammal. Especially useful in the practice of the invention are human glycosyltransferases and transgenic sheep, goats and cows. The heterologous product includes oligosaccharides and glycoconjugates.

Growing community of inventors

Athens, GA, United States of America

Kelley Wilson Moremen